Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-12-09
2009-06-02
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S193100, C424S190100, C424S191100, C424S203100, C424S244100, C424S266100, C424S265100, C424S279100, C424S278100, C424S282100, C424S246100, C424S248100, C424S268100, C424S272100, C435S259000, C435S243000
Reexamination Certificate
active
07541039
ABSTRACT:
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.
REFERENCES:
patent: 5470573 (1995-11-01), Lubitz et al.
patent: 5616686 (1997-04-01), Fischetti et al.
patent: 5786205 (1998-07-01), Fischetti et al.
patent: 5821088 (1998-10-01), Darzins et al.
patent: 5955258 (1999-09-01), Buist et al.
patent: 6027910 (2000-02-01), Klis et al.
patent: 6114147 (2000-09-01), Frenken et al.
patent: 6177083 (2001-01-01), Lubitz
patent: 6423316 (2002-07-01), Riesbeck et al.
patent: 6827940 (2004-12-01), Riordan et al.
patent: 6896887 (2005-05-01), Leenhouts et al.
patent: 7067639 (2006-06-01), Leenhouts et al.
patent: 2003/0180816 (2003-09-01), Leenhouts et al.
patent: 2003/0186851 (2003-10-01), Leenhouts et al.
patent: 2006/0115491 (2006-06-01), Leenhouts et al.
patent: 2008/0193427 (2008-08-01), Kaesler et al.
patent: 3919644 (1990-12-01), None
patent: 198 00 746 (1999-07-01), None
patent: 0 545 352 (1993-06-01), None
patent: 0 712 935 (1996-05-01), None
patent: 02065790 (1990-03-01), None
patent: 10117783 (1998-05-01), None
patent: 2002017357 (2002-01-01), None
patent: WO 91/13155 (1991-09-01), None
patent: WO 92/01791 (1992-02-01), None
patent: WO 94/01567 (1994-01-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 95/31561 (1995-11-01), None
patent: WO 96/00579 (1996-01-01), None
patent: WO 96/11263 (1996-04-01), None
patent: WO 96/40943 (1996-12-01), None
patent: WO 97/28263 (1997-08-01), None
patent: WO 98/07874 (1998-02-01), None
patent: WO 98/42850 (1998-10-01), None
patent: WO 99/25836 (1999-05-01), None
patent: WO 00/44878 (2000-08-01), None
patent: WO 00/53163 (2000-09-01), None
patent: WO 01-09350 (2001-02-01), None
patent: WO 01/54672 (2001-08-01), None
patent: WO 01/91791 (2001-12-01), None
patent: WO 02/101026 (2002-12-01), None
Ramasamy et al, Vaccine, 2006, 24:3900-3908.
Jalava et al, Expert Review of Vaccine, Feb. 2003, 2/1:45-51 (abstract only).
Moorthy et al, Vaccine, 2007, 25:3636-3645.
#Bolotin et al., The Complete Genome Sequence of the Lactic Acid BacteriumLactococcus lactisssp. lactis IL 1403, Genome Research, 2001, pp. 731-753, vol. 11.
#Brown et al., Comparison of Various Procedures for Removing Proteins and Nucleic Acids from Cell Walls ofBacillus subtilis, 1976, pp. 479-488.
#Buist et al., Molecular Cloning and Nucleotide Sequence of the Gene Encoding the Major Peptidoglycan Hydrolase ofLactococcus lactis, a Muramidase Needed for Cell Separation, Journal of Bacteriology, Mar. 1995, pp. 155463, vol. 177, No. 6.
#CIBIK et al., Identification of Mur, an Atypical Peptidoglycan Hydrolase Derived fromLeuconostoc citreum, Applied And Environmental Microbiology, Feb. 2001, pp. 85864, vol. 67, No. 2.
#Fischetti et al., 1996, Gram-positive commensal bacteria for mucosal vaccine delivery. Current Opinions in Biotechnology v7:659-666.
#Furst-Ladani et al., Vaccine, 2000, 18:440-448.
#Gasson et al., Plasmid Complements ofStreptococcus lactisNCDO 712 and OtherLacticStreptococciAfter Protoplast-Induced Curing, Journal of Bacteriology, Apr. 1983, pp. 1-9, vol. 154, No. 1.
#Haslberger et al., J. Biotechnology, 2000, 83:57-66.
#Hatfaludi et al., J. Agric. Food Chem., 2004, 52:5627-5634.
#Huter et al., J. Controlled Release, 1999, 61:51-63.
#Jalava et al., J. Controlled Release, 2002, 85:17-25.
#Kok et al., Nucleotide Sequence of the Cell Wall Proteinase Gene ofStreptococcus cremorisWg2, Applied and Environmental Microbiology, Jan. 1988, p. 231-238, vol. 54, No. 1.
#Kuipers et al., Controlled overproduction of proteins by lactic acid bacteria, Trends in Biotechnology, Apr. 1997, pp. 135-140, vol. 15.
#European Search Report, EP 01 20 2239, dated Jan. 14, 2002.
#Marchart et al., Vaccine, 2003, 21:1415-22.
#Medaglini et al., Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacteriumStreptococcus gordoniiafter oral colonization, Proc. Natl. Acad. Sci.,Jul. 1995, pp. 6868-72, vol. 92.
#Morata et al., Study of the Morphology of the Cell Walls of Some Strains of Lactic Acid Bacteria and Related Species, Journal of Food Protection, 1998, pp. 557-562, vol. 61, No. 5.
#Navarre et al., Proteolytic cleavage and cell wall anchoring at the LPXTG motif of surface proteins in Grampositive bacteria, Molecular Microbiology, 1994, pp. 115-121, vol. 14, No. 1.
#Norton et al., Factors affecting the immunogenicityof tetanus toxin fragment C expressed inLactococcus lactis, FEMS Immunology and Medical Microbiology, 1996, pp. 167-177, vol. 14.
#Norton et al., The immune response toLactococcus lactis: Implications for its use as avaccine delivery vehicle, Federation of European Microbiological Societies, 1994, pp. 249-256, vol. 120.
#Paukner et al., J. Controlled Release, 2004, 94:63-74.
#Paukner et al., J. Drug Targeting, Apr. 2003, 11/3:151-61.
#Poquet et al., HtrA is the unique surface housekeeping protease inLactococcus lactisand is required for natural protein processing, Molecular Microbiology, 2000, p. 1042-1051, vol. 35, No. 5.
#Pozzi et al., 1992, Delivery and expression of a heterologous antigen on the surface ofStreptococci, Infection and Immunity, v60(5):1902-07.
#Ramasamy et al., Antibodies to a merozoite surface protein promote multiple invasion of red blood cells by malaria parasites, Parasite Immunology, 1999, pp. 397-407, vol. 21.
#Ramasamy et al., Studies on glycoproteins in the human malaria parasite Plasmodiunfalciparum. Identification of a myristilated 45kDa merozoite membrane glycoprotein, Immunol. Cell Biol., 1987, pp. 419-424, vol. 65, Pt. 5.
#Robinson et al., Oral vaccination of mice against tetanus with recombinanLactococcus lactis, Nature Biotechnology, Jul. 1997, pp. 653-657, vol. 15.
#Sauve et al., Concentration of Dilute Protein for Gel Electrophoresis, Analytical Biochemistry, 1995, pp. 382-383, vol. 226.
#Stahl et al., Bacterial surface display: trends and progress, Trends in Biotechnology, pp. 185-192, vol. 15.
#Szostak et al., J. Biotechnology, 1996, 44, 161-170.
Buist Girbe
Kok Jan
Kuipers Oscar Paul
Leenhouts Cornelis Johannes
Ramasamy Ranjan
Applied NanoSystems B.V.
Minnifield N. M
TraskBritt
LandOfFree
Immunization with bacterial ghost-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunization with bacterial ghost-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunization with bacterial ghost-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4137078